Clinical Trial Update: Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating androgen deprivation therapy in combination with docetaxel for high-risk prostate cancer in the neoadjuvant setting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Androgen deprivation therapy (Androgen deprivation therapy)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Hongqian Guo | Conditions: Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel | Phase 2 | Status: UNKNOWN